Clinical calculator summary
Original 2005 Sorror HCT-CI
Clinical calculator summary
Original 2005 Sorror HCT-CI
A weighted index of 15 pretransplant comorbidity categories.
Evidence-based context for fast calculator use
- Purpose:
- Reproduce the original HCT-CI score and historical validation-cohort group without making an eligibility or treatment recommendation.
- Population:
- Adults assessed before allogeneic hematopoietic cell transplantation in the original model context.
- Factors:
- Pulmonary and hepatic severity, Thirteen source-defined present/absent comorbidities, Original 0-26 weighted total
- Reference:
- Sorror et al. Blood. 2005;106(8):2912-2919. doi:10.1182/blood-2005-05-2004.
HCT-CI (Transplant Risk)
Select only the highest applicable pulmonary category.
Select only the highest applicable hepatic category.
Clinical Context & Background
Original 2005 HCT-CI = sum of the 15 source-defined comorbidity weights. Pulmonary: none/mild 0, moderate 2, severe 3. Hepatic: none 0, mild 1, moderate/severe 3. All other comorbidities contribute their original 1-, 2-, or 3-point weight when present.Reference Data
| Score | Original Group | 2-Year NRM | 2-Year Overall Survival |
|---|---|---|---|
| 0 | Low risk | 14% | 71% |
| 1 - 2 | Intermediate risk | 21% | 60% |
| >= 3 | High risk | 41% | 34% |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use before allogeneic HCT, based on comorbidity status at transplantation.
- Apply the original source definitions and local laboratory pulmonary/hepatic assessments.
How To Interpret
- Sum all 15 source-defined weights.
- Scores 0, 1-2, and >=3 match the original low-, intermediate-, and high-risk validation-cohort rows.
What To Do Next
- Integrate the score with disease, donor, conditioning, functional, geriatric, and patient-specific assessment.
- Use multidisciplinary transplant evaluation rather than the HCT-CI alone.
Limitations
- Not the age-adjusted, pediatric, autologous-HCT, or post-transplant model.
- Historical 2-year outcomes are cohort observations, not individualized predictions.
- Does not independently determine transplant eligibility or treatment.
Validated Population
Adults assessed before allogeneic HCT in the original 2005 derivation and validation cohorts.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through all fifteen visible controls at HCT-CI totals 0, 1, and 26.
- The expected historical low/intermediate/high group outcomes matched exactly.
- No unexpected N/A, stale control, literal undefined/null value, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/hct-ci-hematopoietic-cell-transplant-comorbidity-index-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/hct-ci-hematopoietic-cell-transplant-comorbidity-index.json.
: Full validation test
- 512/512 source-weight, score-boundary, clinical-definition, strict-input, UI/reset, trace, wording, immutability, registry, and no-panel checks passed with zero score or classification mismatches.
- Scope is the original 2005 pre-allogeneic-HCT model; no panel calculates HCT-CI or inherits this verification status.
: Calculation and input-contract correction
- Replaced favorable numeric defaults and Object.values/Number coercion with 15 mandatory semantic categories, exact-key validation, and rejection of legacy points, malformed values, missing or extra fields.
- Corrected pulmonary, hepatic, renal, obesity, treated-diabetes, cardiac and prior-solid-tumor definitions and boundaries; preserved the original 0-26 weighted total and 0, 1-2, and 3-or-higher groups.
- Added all 15 contributions, a reconciled trace, matched 2-year validation-cohort NRM and survival row, and explicit exclusion of individualized prognosis, eligibility, and treatment claims.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Frequently Asked Questions
When should HCT-CI (Transplant Risk) be used?
Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.
Can HCT-CI (Transplant Risk) determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.